PROGNOSTIC IMPACT OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME NEGATIVE PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. Djunic I. 06/09/16; 134509; PB1609
Dr. Irena Djunic
Contributions
Contributions
Abstract
Abstract: PB1609
Type: Publication Only
Background
Prognostic influence of immunophenotypic markers in acute lymphoblastic leukemia (ALL) is well recognized. The prognostic significance of CD20 expression in precursor B-cell acute lymphoblastic leukemia (ALL) has been investigated first in childhood and than in adult with conflicting results.
Aims
The aim of this study was to determine the prognostic impact of CD20 expression on outcome in adult patients with Philadelphia chromosome negative (Ph-) precursor B-cell ALL. The second goal was to estimate, in comparison to the results, is there a need to incorporate monoclonal anti CD20 antibody (Rituximab) in routine treatment of these patients, where it is not available, to improve their outcome.
Methods
This single center study involved 122 patients with de novo Ph- precursor B-cell ALL diagnosed in period 2003 – 2015, with follow-up period of 72 months. For CD20 antigen expression, detected by flow-cytometry, the cut-off value ≥ 20% was taken as positive (CD20+). As risk factors for rate of complete remission (CR) and overall survival (OS) in months in this cohort of patients the following were evaluated: age, leukocytosis (<30x109/L vs. ≥30109/L) and CD20 expression. In period of 2003 – 2006, the patients were treated with regimen LALA 94, while in period 2007-2015 they were treated with protocol HyperCVAD. The applying of monoclonal anti CD20 antibody (Rituximab) with chemotherapy was no available.
Results
The mean age of the patients was 42 years (range 19-77). The CD20+ was recorded in 41 (33.6%) of patients. The estimated risk factors had no influence to achievement of CR. However, the univariate analysis showed that age ≥ 55 years (p = 0.035) and CD20+ (p = 0.042) had significant impact on poor OS. Multivariate analysis indicated CD20+ as the most important risk factor for poor OS: p = 0.001, HR = 3.853(95% CI = 1.755-8.461.
Conclusion
This study showed the negative impact of CD20 expression in Ph- precursor ALL on outcome of these patients. Also, we point out the importance of incorporation monoclonal anti CD20 antibody (Rituximab) in combine with chemotherapy in routine treatment of these patients to improve its outcome.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, CD20, Prognostic factor
Type: Publication Only
Background
Prognostic influence of immunophenotypic markers in acute lymphoblastic leukemia (ALL) is well recognized. The prognostic significance of CD20 expression in precursor B-cell acute lymphoblastic leukemia (ALL) has been investigated first in childhood and than in adult with conflicting results.
Aims
The aim of this study was to determine the prognostic impact of CD20 expression on outcome in adult patients with Philadelphia chromosome negative (Ph-) precursor B-cell ALL. The second goal was to estimate, in comparison to the results, is there a need to incorporate monoclonal anti CD20 antibody (Rituximab) in routine treatment of these patients, where it is not available, to improve their outcome.
Methods
This single center study involved 122 patients with de novo Ph- precursor B-cell ALL diagnosed in period 2003 – 2015, with follow-up period of 72 months. For CD20 antigen expression, detected by flow-cytometry, the cut-off value ≥ 20% was taken as positive (CD20+). As risk factors for rate of complete remission (CR) and overall survival (OS) in months in this cohort of patients the following were evaluated: age, leukocytosis (<30x109/L vs. ≥30109/L) and CD20 expression. In period of 2003 – 2006, the patients were treated with regimen LALA 94, while in period 2007-2015 they were treated with protocol HyperCVAD. The applying of monoclonal anti CD20 antibody (Rituximab) with chemotherapy was no available.
Results
The mean age of the patients was 42 years (range 19-77). The CD20+ was recorded in 41 (33.6%) of patients. The estimated risk factors had no influence to achievement of CR. However, the univariate analysis showed that age ≥ 55 years (p = 0.035) and CD20+ (p = 0.042) had significant impact on poor OS. Multivariate analysis indicated CD20+ as the most important risk factor for poor OS: p = 0.001, HR = 3.853(95% CI = 1.755-8.461.
Conclusion
This study showed the negative impact of CD20 expression in Ph- precursor ALL on outcome of these patients. Also, we point out the importance of incorporation monoclonal anti CD20 antibody (Rituximab) in combine with chemotherapy in routine treatment of these patients to improve its outcome.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, CD20, Prognostic factor
Abstract: PB1609
Type: Publication Only
Background
Prognostic influence of immunophenotypic markers in acute lymphoblastic leukemia (ALL) is well recognized. The prognostic significance of CD20 expression in precursor B-cell acute lymphoblastic leukemia (ALL) has been investigated first in childhood and than in adult with conflicting results.
Aims
The aim of this study was to determine the prognostic impact of CD20 expression on outcome in adult patients with Philadelphia chromosome negative (Ph-) precursor B-cell ALL. The second goal was to estimate, in comparison to the results, is there a need to incorporate monoclonal anti CD20 antibody (Rituximab) in routine treatment of these patients, where it is not available, to improve their outcome.
Methods
This single center study involved 122 patients with de novo Ph- precursor B-cell ALL diagnosed in period 2003 – 2015, with follow-up period of 72 months. For CD20 antigen expression, detected by flow-cytometry, the cut-off value ≥ 20% was taken as positive (CD20+). As risk factors for rate of complete remission (CR) and overall survival (OS) in months in this cohort of patients the following were evaluated: age, leukocytosis (<30x109/L vs. ≥30109/L) and CD20 expression. In period of 2003 – 2006, the patients were treated with regimen LALA 94, while in period 2007-2015 they were treated with protocol HyperCVAD. The applying of monoclonal anti CD20 antibody (Rituximab) with chemotherapy was no available.
Results
The mean age of the patients was 42 years (range 19-77). The CD20+ was recorded in 41 (33.6%) of patients. The estimated risk factors had no influence to achievement of CR. However, the univariate analysis showed that age ≥ 55 years (p = 0.035) and CD20+ (p = 0.042) had significant impact on poor OS. Multivariate analysis indicated CD20+ as the most important risk factor for poor OS: p = 0.001, HR = 3.853(95% CI = 1.755-8.461.
Conclusion
This study showed the negative impact of CD20 expression in Ph- precursor ALL on outcome of these patients. Also, we point out the importance of incorporation monoclonal anti CD20 antibody (Rituximab) in combine with chemotherapy in routine treatment of these patients to improve its outcome.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, CD20, Prognostic factor
Type: Publication Only
Background
Prognostic influence of immunophenotypic markers in acute lymphoblastic leukemia (ALL) is well recognized. The prognostic significance of CD20 expression in precursor B-cell acute lymphoblastic leukemia (ALL) has been investigated first in childhood and than in adult with conflicting results.
Aims
The aim of this study was to determine the prognostic impact of CD20 expression on outcome in adult patients with Philadelphia chromosome negative (Ph-) precursor B-cell ALL. The second goal was to estimate, in comparison to the results, is there a need to incorporate monoclonal anti CD20 antibody (Rituximab) in routine treatment of these patients, where it is not available, to improve their outcome.
Methods
This single center study involved 122 patients with de novo Ph- precursor B-cell ALL diagnosed in period 2003 – 2015, with follow-up period of 72 months. For CD20 antigen expression, detected by flow-cytometry, the cut-off value ≥ 20% was taken as positive (CD20+). As risk factors for rate of complete remission (CR) and overall survival (OS) in months in this cohort of patients the following were evaluated: age, leukocytosis (<30x109/L vs. ≥30109/L) and CD20 expression. In period of 2003 – 2006, the patients were treated with regimen LALA 94, while in period 2007-2015 they were treated with protocol HyperCVAD. The applying of monoclonal anti CD20 antibody (Rituximab) with chemotherapy was no available.
Results
The mean age of the patients was 42 years (range 19-77). The CD20+ was recorded in 41 (33.6%) of patients. The estimated risk factors had no influence to achievement of CR. However, the univariate analysis showed that age ≥ 55 years (p = 0.035) and CD20+ (p = 0.042) had significant impact on poor OS. Multivariate analysis indicated CD20+ as the most important risk factor for poor OS: p = 0.001, HR = 3.853(95% CI = 1.755-8.461.
Conclusion
This study showed the negative impact of CD20 expression in Ph- precursor ALL on outcome of these patients. Also, we point out the importance of incorporation monoclonal anti CD20 antibody (Rituximab) in combine with chemotherapy in routine treatment of these patients to improve its outcome.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, CD20, Prognostic factor
{{ help_message }}
{{filter}}